Larry J Copeland MD

Larry J Copeland MD
ProfessorCollege of Medicinecopeland.7@osu.edu
M210 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7642Fax: 614-293-5877
  • Experimental Therapeutics

Current Publications

  • Eisenhauer ELFeasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer-A Phase 1 Study.Int J Gynecol Cancer 3/19/2014
  • Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK, Walker JLPrognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.Gynecol Oncol 130(1) 12-8 7/1/2013
  • Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23(5) 833-8 6/1/2013
  • McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129(1) 135-9 4/1/2013
  • Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129(1) 103-6 4/1/2013
  • McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128(1) 44-8 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu